MSD is involved in research and development in various areas including antibiotics, vaccines, HIV, diabetes, and oncology. The company is self-described as focused on health literacy and responsible corporate practices.

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

David R. Walt

Quanterix Corporation

PHOENIX group operates in the healthcare sector, focusing on pharmaceutical wholesale and distribution services. The company has set climate targets to achieve carbon neutrality in its operations by 2030.

Metric
Company Name	MSD	Quanterix Corporation	PHOENIX group
Symbol		QTRX
MSH ID	PT:MSD	COM:QUANTERIX	EU:MCKESSON
Market	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Pharmaceuticals	Medical - Devices	Pharmaceuticals
Country	PT	US	DE
Stage
Employee Count		441
Website	msd.pt	quanterix.com	mckesson.eu
LinkedIn		quanterix
Founders

Metric
Market Cap	508.23M
Enterprise Value
Monthly Web Traffic		76.57K
Web Traffic Growth		0.10
Valuation
Raised Capital

Metric
Revenue		121.14M
Revenue (LTM)
Revenue (NTM)
Gross Profit		69.42M
EBITDA		-38.25M
Operating Income		-49.70M
Net Income		-32.33M
EPS		-0.86
Diluted EPS		-0.86
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.55
Operating Profit Margin		-0.42
EBITDA Margin		-0.32
Net Profit Margin		-0.27
Return on Equity		-0.09
Return on Assets		-0.08
Return on Capital Employed		-0.13

PT:MSD

MSD

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-22.85
P/B Ratio		2.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		7.43
EV Multiple		-8.82

Metric
Days Sales Outstanding		76.07
Days Payables Outstanding		34.80
Days Inventory Outstanding		176.13
Operating Cycle		266.18
Cash Conversion Cycle		231.93
Asset Turnover		0.31

Metric
Operating Cash Flow		-18.90M
Free Cash Flow		-22.69M
Cash Flow to Debt		-0.46
Operating Cash Flow/Sales		-0.16
Free Cash Flow Yield		-0.02

Metric
Cash & Equivalents		174.42M
Accounts Receivable		-6.70M
Inventory		22.36M
Goodwill
Debt to Capitalization		0.11
Debt to Assets		0.10
Current Ratio		10.84
Quick Ratio		10.57

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.14
R&D to Revenue		0.20
SG&A to Revenue		0.42